Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368849 · ClinicalTrials.gov registry record · Phase 2
Atomoxetine and Huntington's Disease
A Phase 2 study of Huntington Disease and Chorea, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00368849 is a Phase 2 study of Huntington Disease and Chorea that has completed, run by University of Iowa. The registered enrollment target is 20 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00368849, a Phase 2 study of Huntington Disease and Chorea, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit disorder (ADD).
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG atomoxetine
Study Locations (1)
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368849
The ClinicalTrials.gov registry entry for NCT00368849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (97% lower). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT00368849 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT00368849 about?
NCT00368849 is a clinical study titled "Atomoxetine and Huntington's Disease". The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit d...
What is the current status of trial NCT00368849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-11. Estimated completion is 2008-02.
What conditions does trial NCT00368849 study?
This clinical trial studies the following conditions: Huntington Disease, Chorea.
What interventions are being tested in trial NCT00368849?
The interventions under investigation include: Matching Placebo (DRUG), atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00368849?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00368849 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.